(Q45340364)

13 December 2017

Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial (English)

1 reference

13 December 2017

3

M A Banerji

1 reference

13 December 2017

15

R A DeFronzo

1 reference

13 December 2017

G A Bray

1

1 reference

13 December 2017

S R Smith

2

1 reference

13 December 2017

D Tripathy

4

1 reference

13 December 2017

S C Clement

5

1 reference

13 December 2017

T A Buchanan

6

1 reference

13 December 2017

R R Henry

7

1 reference

13 December 2017

A E Kitabchi

8

1 reference

13 December 2017

S Mudaliar

9

1 reference

13 December 2017

N Musi

10

1 reference

13 December 2017

R E Ratner

11

1 reference

13 December 2017

D C Schwenke

12

1 reference

13 December 2017

F B Stentz

13

1 reference

13 December 2017

P D Reaven

14

1 reference

13 December 2017

7 May 2013

1 reference

Diabetes, Obesity and Metabolism

13 December 2017

1 reference

13 December 2017

15

1 reference

13 December 2017

10

1 reference

13 December 2017

931-937

1 reference

Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002.

13 December 2017

1 reference

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial

21 January 2018

1 reference

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes

21 January 2018

1 reference

Pioglitazone for diabetes prevention in impaired glucose tolerance.

21 January 2018

1 reference

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

21 January 2018

1 reference

Actos Now for the prevention of diabetes (ACT NOW) study

21 January 2018

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

Use of thiazolidinediones and fracture risk

21 January 2018

1 reference

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes

21 January 2018

1 reference

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.

21 January 2018

1 reference

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

21 January 2018

1 reference

Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.

21 January 2018

1 reference

Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes

21 January 2018

1 reference

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus

21 January 2018

1 reference

21 January 2018

1 reference

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

21 January 2018

1 reference

Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial

21 January 2018

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

21 January 2018

1 reference

Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones

21 January 2018

1 reference

Differential recruitment and differential regulation by physiological amines of fat cell beta-1, beta-2 and beta-3 adrenergic receptors expressed in native fat cells and in transfected cell lines

21 January 2018

1 reference

Simulated change in body fatness affects Hologic QDR 4500A whole body and central DXA bone measures

21 January 2018

1 reference

Errors in dual-energy X-ray absorptiometry of the lumbar spine owing to fat distribution and soft tissue thickness during weight change

21 January 2018

1 reference

Anomalies in the measurement of changes in total-body bone mineral by dual-energy X-ray absorptiometry during weight change

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12099

1 reference

13 December 2017

1 reference